Skip to main content

Market Overview

AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

Shares of thinly-traded nano-cap biotech AzurRx BioPharma Inc (NASDAQ: AZRX) are trading sharply lower following a clinical readout from the company.

What Happened

AzurRx is working on developing non-systemic, recombinant therapies for gastrointestinal diseases. The company said the results of the Phase 2 OPTION trial that is evaluating its MS1819 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis showed that the primary efficacy endpoint of coefficient of fat absorption, or CFA, was comparable to that in a previous Phase 2 study in patients with chronic pancreatitis.

The dose used in both studies was 2 gram per day, in line with the agreement with the FDA as a bridging dose.

See Also: Axsome Shares Flirt With Record High: How Much Upside Is Left?

Despite the study not being powered for statistical significance, the data showed meaningful efficacy results, with about 50% of patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies, or PERT, AzurRx said.

However, the company noted CFA of the MS1819 treatment arm was 56% compared to 86% for the PERT treatment arm.

Suggesting that protease supplementation is not required with MS1819, the coefficient of nitrogen absorption was comparable between the MS1819 arm and the PERT arm.

"With these data showing MS1819 to be safe and to have the potential to support fat absorption, we have considerable reason to be optimistic for the next steps in non-porcine enzyme development," said Dr. Michael Konstan, the principal investigator of the study.

What Next

AzurRx said it looks forward to meeting with the FDA before the year end to discuss these results and its next steps. The company plans to discuss with the regulatory agency the Phase 2b/3 trial design exploring the use of higher doses and/or enteric-coated capsules to ensure higher MS1819 activity in the duodenum.

AzurRx shares were down 30.32% to 62 cents at time of publication.


Related Articles (AZRX)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks FDA Markets Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at